JAMES C YAO to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications JAMES C YAO has written about Clinical Trials, Phase II as Topic.
Connection Strength
1.266
-
Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol. 2015 Sep 10; 33(26):2914-9.
Score: 0.407
-
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013; 18(5):525-32.
Score: 0.347
-
In reply. Oncologist. 2013; 18(11):1240-1.
Score: 0.340
-
Perspectives in the development of novel treatment approaches. Tumori. 2010 Sep-Oct; 96(5):858-73.
Score: 0.072
-
Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park). 2008 Dec; 22(14):1617-23; discussion 1623-4, 1629.
Score: 0.064
-
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9.
Score: 0.022
-
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40.
Score: 0.014